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The evidence which has finally resulted in the general acceptance of the concept
that there are substances present in hypothalamic tissue which inhibit the release
of melanocyte-stimulating hormone (MSH) from the pituitary glands of mammals
as well as amphibians has been summarized in several recent reviews (1-3). Al-
though the chemical structures of several compounds with such activity are known,
it is still uncertain which one of these, if not a different one, is the actual hormone.
Both a tripeptide, Pro-Leu-Gly-NH2, and a pentapeptide, Pro-His-Phe-Arg-Gly-
NH2, have been isolated from bovine hypothalamic tissue and structurally identified
(4, 5). Since purification of the bovine extract involved heating to boiling in dilute
acetic acid followed by rapid cooling (6), the recent suggestion by Hadley, Bower,
and Hruby (7) that hypothalamic extracts heated to boiling under undefined condi-
tions lose their ability to inhibit MSH release probably can be dismissed as a techni-
cal problem. The assay used for following the isolation of the two peptides is based
on the lightening of the skin of a frog which has been previously darkened by
destruction of the hypothalamus (8, 9). Pro-Leu-Gly-NH2 can be formed by incu-
bating oxytocin with an enzyme found in hypothalamic tissue and has been re-
ported previously to inhibit MSH release in the rat also (10). However, Bower
et al. (11) did not find any MSH-release inhibiting factor (MIF) activity of Pro-
Leu-Gly-NH2 (MIF-I) in the frog or rat. Why they failed to find activity in the
frog, Rana pipiens, is easy to understand: they injected MIF-I into the dorsal
lymph sac, a procedure already shown to be ineffective, and they also incubated
MIF-I with pituitaries for 4 hr, a time which results in essentially complete in-
activation of the material (9). It is also possible that an inactive (12) batch of
MIF-I was tested. The reason for the inability of Bower et al. to find the activity
of MIF-I which had been reported by Celis et al. (10) for rats is not known.
Alternatively, Bower et al. proposed that tocinoic acid, Cys-Tyr-Ile-Gln-Asn-Cys-
OH, the cyclic pentapeptide ring of oxytocin, or its amide, tocinamide, is more
likely to be MIF (11). Interestingly, Celis et al. (13) have suggested that if the
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tocinoic acid ring is opened, the resulting hexapeptide, H-Cys-Tyr-Ile-Gln-Asn-
Cys-OH, is the MSH-releasing hormone (MRH) but they found no activity of
tocinoic acid in the rat (14).
Thus, four compounds have been found by different investigators to possess MIF
activity. Only Pro-Leu-Gly-NH2 (MIF-I) and Pro-His-Phe-Arg-Gly-NH2 (MIF-
II) have been isolated from hypothalamic tissue, but it is reasonable to expect
that the other two compounds may also be present in hypothalamic tissue.
SKIN LIGHTENING EFFECTS IN THREE SPECIES OF AMPHIBIANS
When Hruby et al. reported (15) that tocinoic acid and tocinamide inhibit MSH
release from the bullfrog (Rana catesbeiana) and the toad (Bufo marinus) but
not the frog (Rana pipiens), the question of species specificity was raised. Their
findings were based upon an in vitro assay, presumably involving incubation for
4 hr (15). We tested tocinoic acid and MIF-I in the same three species of am-
phibians used by Hruby et al., namely R. pipiens, B. marinus, and R. catesbeiana.
Using doses of tocinoic acid as high as 100/jg, we were unable to find significant
(melanocyte index less than 4.0) lightening (8) of these animals darkened
(melanocyte index of 5.0) by destruction of the hypothalamus. Doses of 10 ng,
50 ng, 100 ng, 1 Mg, 10jug, 50 Mg, and 100 MAg were tested. In the frog and bullfrog,
there was a tendency for slightly more lightening with increasing doses of tocinoic
acid. In the toad, however, the maximum lightening of the skin seemed to occur
with a dose of 1 Mg, not with doses 10 and 100 times greater or smaller. Neverthe-
less, at no dose was the reduction in melanocyte index as great as that seen with
only 50 ng of MIF-I; this lightening became greater with increasing doses of
MIF-I but was less evident with smaller doses.
The biological activity of MIF-I determined in the frog was not seen when a
similar assay procedure was used in the other two species. That is, MIF-I, when
applied to the pituitary glands of either the toad or bullfrog in doses from 10 ng
to 100 MAg, did not reduce the melanocyte index in their skin to 4.0. Application
to the pituitary of 100 Mig MIF-Il resulted in significant reduction in the melanocyte
index of the frog, but no lightening of the toad or bullfrog. With N. Yanaihara,
we considered the unlikely possibility that during the structural determination on
a microscale of MIF-II, which has certain amino acids in common with the active
core of MSH, a tryptophyl residue might have been overlooked. Accordingly,
Yanaihara synthesized Pro-His-Phe-Arg-Trp-Gly-NH2 as well as MIF-Il. At a dose
of 100 yg, MIF-II significantly lightened the lesioned R. pipiens, as expected. The
hexapeptide containing Trp (Pro-His-Phe-Arg-Trp-Gly-NH,) was not active in the
frog but did have a slight tendency to lighten the lesioned toad. Pressinoic acid
(40 Mg) and pressinamide (110 Mg) were inactive in all three species of am-
phibians, as had been found previously by Hruby et al. (15). We also failed to
find significant lightening in any of the three species with 100ug tocinamide as
well as two other analogs of MIF-I and MIF-Il synthesized by Yanaihara: pyro-
Glu-His-Phe-Arg-Gly-NH2 and Ac-Pro-Leu-Gly-NH2. The slight lightening caused
by 100ug doses of the acetylated MIF-I (Ac-Pro-Leu-Gly-NH2) occurred in all
three species of amphibians tested. Perhaps in our assay system there are variations
in the rate of penetration of certain test substances into the pituitary after being
applied to its surface, or maybe materials applied to the surfaces of the pituitary
glands from different species are subject to varying rates of inactivation. These
618findings support the concept that species specificity may exist for the compounds
proposed to have MIF activity, but the specificity appears to differ among different
laboratories using different techniques of assay.
STABILITY
Part of the problem may lie in the relative instability of MIF-I as determined
in the lesioned frog. When MIF-I is shaken in a Dubnoff metabolic incubator at
35-370C, it rapidly loses activity. This occurs in Kreb's ringer bicarbonate, (with
or without calcium), frog ringer's solution, saline, and serum from the rat, frog,
or human being. It does not seem to make any great difference whether MIF-1
is shaken in an atmosphere of nitrogen or 95% oxygen-5% carbon dioxide. Coat-
ing the incubation beakers with silicon or using cerebral spinal fluid instead cf
serum also fails to maintain activity. Although the loss of activity is retarded when
higher concentrations are used (e.g., 1 mg/ml instead of 100 tg/ml), there still
is significant loss of activity in less than 2 hr.
Even if the material is refrigerated at 40C, it appears to retain its biological
activity in the lesioned frog for less than 4 days. Under these conditions, an acidic
solution seems to result in less loss of activity than saline. More MIF activity is
retained by storage of the solution at -200C (Table 1), although the duration
of this benefit is limited to less than 10 days.
It is not known whether the instability of MIF-I explains the difficulty we have
been having in demonstrating its activity in the rat in an in vivo situation. We
have tried several different systems without much success. After plasma MSH levels
have been elevated by such compounds as phenothiazines or haloperidol, injection
of MIF-I or tocinoic acid into the lateral ventrical, third ventrical, hypothalamus,
or pituitary gland did not consistently result in decreased plasma levels of MSH.
Incidentally, ketamine also was found not to cause any change in plasma MSH
levels. Initially, in preliminary studies performed with J. Sandow, direct infusion
of MIF-I into the pituitary portal system seemed to inhibit MSH release into the
plasma, but the variation among samples was so great that the effect was not sta-
tistically significant.
TABLE I
ACTIVITY IN LESIONED FiROGs OF ATIF-1 AFTEIR STORAGE FORT 4 D).AYS
40C -Q2o0C
(refrigerator) (freezer)
Cotncenitratioii (melanocyte (inelanocyte
Diluent (nmg/ml) index)a ind(iex)
0.1 3!1 acetic aci(l 10 4 Ai5 4.05
1 4.30 4.15
0.1 4.35 4.30
0.1 N hydrochloric acid 10 4.2S 4.05
1 4.30 4.07
0.1 4.35 4.25
Saline 10 4.45 4.22
1 4.42 4.30
0.1 4.45 4.32
a The melanocyte index is inversely related to melanocyte-lightening (melanin granule aggregation)
activity; 50 ng of MIF-I consistelltly lowers the melanocyte index from 5.0 to less than 4.0,
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TABLE 2
POTENTIATION OF BEHAVIOR BY DOPA IN MICE 1 HR AFTER INJECTION OF TEST SUBSTANCE
Dose Tocinoic
(mg/kg, ip) MIF-I MIF-II acid MSH Control
0.1 3a 1 1 1 1
0.2 3 1 2 2 1
0.4 3 2 2 3 1
0.8 3 3 3 3 1
a Mean degree of potentiation: 1 = slight; 2 = moderate; 3 = marked.
EFFECTS OF MIF ON THE CENTRAL NERVOUS SYSTEM (CNS)
We have reported that MIF-I is active in several animal models of Parkinson's
disease and mental depression and a preliminary report indicates that it may also
be beneficial in patients suffering with parkinsonism (16-19). These effects do not
require the presence of the pituitary gland and thus show for the first time that
hypothalamic hormones may have extraendocrine effects.
One of these animal models involves potentiation by MIF-I of the behavioral
effects of DOPA (16). Table 2 indicates that some of the other substances discussed
here (in the present paper) also potentiate the effects of DOPA. Thus, MIF-II,
tocinoic acid, and MSH all have some activity in this test system, but none of
them are as active as MIF-I. That this finding cannot be explained by a simple
effect of MIF-I or MSH upon motor activity has been shown in a separate study
measuring activity where body weight, food intake, and water ingestion were also
unchanged by MIF-I or MSH (20).
Although a pilot study seemed to indicate that MIF-I shared with MSH the
ability to inhibit step-down latency in rats in a passive avoidance situation, no sta-
tistically significant difference was found (21). Habituation to a loud buzzer did
not seem to be affected by administration of MIF. It also appeared that MIF had
a slight tendency to delay extinction of an operant response for food in a Skinner
box, but again the wide variation among the rats made it impossible to draw any
conclusions.
The mechanism by which MIF-I exerts actions upon the CNS is not known. Frogs
pretreated with a monoamine-oxidase inhibitor and reserpine show a slight loss
of the righting reflex (22). We found this effect to be greatly enhanced by the
tricyclic antidepressants but unchanged by MIF-I. This system is considered (22)
to involve 5-hydroxytryptamine in the CNS. In another study, a dose of 100 ,ug
6-hydroxydopamine did not lighten the lesioned frog. Furthermore, after 5 days
of treatment of mice with MIF-I (5-20 mg/kg), the total brain content of dopa-
mine, norepinephrine, or serotonin did not show any significant change (23). The
mechanism of action of MIF-I on the CNS is not known, but, at the moment
(January 1973), it is still important to demonstrate that CNS actions of MIF do
occur.
SUMMARY
The existence of a hypothalamic inhibitor of MSH release is now well estab-
lished. Four compounds, two of which have been isolated from hypothalamic tis-
sue, have been reported to have MIF activity. Species specificity appears to be
involved although problems in stability of the compound may also contribute to
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the problems encountered. Apart from the actions of MIF mediated by MSH upon
the skin color of amphibians, these compounds also have an effect upon the ner-
vous system. Thus, MIF affects tissue derived from the neural crest both directly
(CNS) and indirectly (melanocytes).
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